<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:department>Cardiovascular Sciences</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/26872B0C-B0B2-424F-8FD6-8D75C650C9FD"><gtr:id>26872B0C-B0B2-424F-8FD6-8D75C650C9FD</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:otherNames>Philip</gtr:otherNames><gtr:surname>Brindle</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FE019404%2F1"><gtr:id>9A08FC57-4B21-47F3-A15D-CB6D61278BCB</gtr:id><gtr:title>A strategy for rapid directed modification of protein binding properties</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/E019404/1</gtr:grantReference><gtr:abstractText>Development of new protein-based drugs would be greatly helped if there was a straightforward and rapid method by which proteins could be changed so they would bind more specifically and strongly to their targets within the body. This would allow drugs with fewer side effects and higher potency to be made. In addition, changing proteins so they can bind to new disease targets would allow new types of drugs to be developed. This project aims to establish and test a novel method for changing protein binding very much more easily and rapidly than ever before.</gtr:abstractText><gtr:technicalSummary>This project seeks to establish and test a new method for straightforward, rapid modification of recognition and binding characteristics of proteins. The method will find applications in a number of areas including development of biological therapeutics and biosensors. The proposed strategy will utilize mutagenesis together with surface display. This will be combined with selection of protein variants with specific binding characteristics based on their interaction with fluorescently-labelled partners. The approach aims to generate novel proteins with specified binding properties more rapidly and easily than previously possible.</gtr:technicalSummary><gtr:fund><gtr:end>2008-04-18</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2007-04-19</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>92590</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Laboratory of Molecular Biology (LMB)</gtr:department><gtr:description>Ang2 ligand trap</gtr:description><gtr:id>4A92C3F1-8AF0-4CC7-8574-DA4C005B0718</gtr:id><gtr:impact>Publication in JBC and patent. The collaboration was covered by an agreement during my secondment to LMB, I have a less formal continuing collaboration with the LMB PI ongoing</gtr:impact><gtr:partnerContribution>Expertise in using the DT40 cell line and access to facilities and other expertise</gtr:partnerContribution><gtr:piContribution>I used the expertise built up during the grant period to set up the evolution system at LMB and evolve the protein</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Project result communications</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>199C76F5-96BB-4981-88C4-BABFFA27260E</gtr:id><gtr:impact>The method we developed during this project and resulting biological insight and potential therapeutic have been presented at a number of seminars and meetings, for example 2014 Harden Conference on Receptor tyrosine kinases. In addition, a summary of the method was published in BBSRC Business magazine (December 2013) and the publicity regarding the paper carried on a number of websites including MRC LMB, BBSRC and Science Daily.

Several enquiries from scientists about using the technique as well as the molecule created</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>196423</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>AC840060-3675-4BE9-BD73-6FEC36C7CF67</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The findings have two potential impacts - a new biological therapeutic and a method for creating further protein-based therapeutics and biotechnology products. We have patented the potential therapeutic and are developing this to a stage when it can be tested in vivo. This is likley to be the stage at which impact is most likely to occur - if the protein is taken up by pharma for further development. If so impact would be societal and economic.</gtr:description><gtr:id>C5EFC0EA-7E58-47FA-9B7E-E624E45C2D5A</gtr:id><gtr:impactTypes/></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A ligand trap for blocking the effects of Ang2, a ligand that drives vascular inflammation and has a key role in cancer and cardiovascular disease.</gtr:description><gtr:id>23A358A9-AAA9-4859-ABD0-C34F484B6D20</gtr:id><gtr:impact>This PCT filing followed on from an initial UK patent application in December 2012. The discovery is currently being made available for licenesing via MRCT. This is the original ligand trap that we are now developing further with BHF funding.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>PCT/GB2013/053392</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Angiopoietin-2 specific Tie2 receptor</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>The project has now provided proof of concept for a new method to generate proteins with specific binding characteristics. This will be useful for application to generation of therapeutics as well as biotechnological uses. In addition the project has shown that this method can be used to help define what parts of a protein contribute to specific aspects of its function.</gtr:description><gtr:exploitationPathways>The work provides a method that can be used to create new proteins for use in medical and biotechnology applications. The project has produced a new protein with therapeutic potential that could have use as a novel drug.</gtr:exploitationPathways><gtr:id>95295E0B-CFDD-48A5-9A2E-BB3FD5013811</gtr:id><gtr:sectors><gtr:sector>Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>New variant of Tie2 ectodomain that acts as a ligand trap to block pathological actions of Ang2. We have developed the initial variant with funding from the original BBSRC Tools and Resources Development grant and subsequently in collaboration with MRC LMB.</gtr:description><gtr:id>74375AB7-D008-41F8-9BEB-6ACB9197F0CF</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Ang2 ligand trap</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>New protein variant with therapeutic potential</gtr:description><gtr:id>B8E9D95A-4B62-4B24-9862-0095261157EC</gtr:id><gtr:impact>Publication of the method and evolved molecule, patent, conference presentations</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Ang2 Ligand Trap</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/960BD91C-C838-4935-82AA-541EC16A0FE0"><gtr:id>960BD91C-C838-4935-82AA-541EC16A0FE0</gtr:id><gtr:title>Directed evolution of an angiopoietin-2 ligand trap by somatic hypermutation and cell surface display.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fcca5bfacb092d81cf667a5d77119229"><gtr:id>fcca5bfacb092d81cf667a5d77119229</gtr:id><gtr:otherNames>Brindle NP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/E019404/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>